GlioCART GmbH

CAR-T cell therapy targeting glioblastoma.

Glioblastoma (GBM) is the most aggressive and fatal brain cancer, with a median survival of just 18 months.
We have developed a CAR-T cell therapy for GBM, targeting the tumor directly while secreting a CD47-blocker to reprogram macrophages to mount a coordinated immune attack against the tumor.
With our therapy, we expect increased survival rates and significantly reduced side effects compared to standard-of-care treatments and other new product developments (e.g. ADCs).
Our program is on track for IMPD submission and first-in-human (FIH) clinical trial initiation in 2026.
The company is a spin-off from University of Basel.
Founders:
Prof. Dr. Gregor Hutter (CMO),
Dr. Patrice Zeis (COO),
Dr. Valerio Sabatino (CSO),
Dieter Willmann (CEO)

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

09.12.2025

Exclusive Option Agreement secured with the University of Basel for the underlying IP license

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2025

Website